Evidence map›Paper›PMID 37131711›Full record

ArticlebioRxiv : the preprint server for biology2023

A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication and pathogenesis

Taha Y Taha, Rahul K Suryawanshi, Irene P Chen, Galen J Correy, Patrick C O'Leary, Manasi P Jogalekar, Maria McCavitt-Malvido, Morgan E Diolaiti, Gabriella R Kimmerly, Chia-Lin Tsou and 5 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Taha Y TahaGladstone Institutes, San Francisco, CA 94158.
Rahul K SuryawanshiGladstone Institutes, San Francisco, CA 94158.
Irene P ChenGladstone Institutes, San Francisco, CA 94158.
Galen J CorreyUniversity of California San Francisco, San Francisco, CA 94158.
Patrick C O'LearyUniversity of California San Francisco, San Francisco, CA 94158.
Manasi P JogalekarUniversity of California San Francisco, San Francisco, CA 94158.
Maria McCavitt-MalvidoGladstone Institutes, San Francisco, CA 94158.
Morgan E DiolaitiUniversity of California San Francisco, San Francisco, CA 94158.
Gabriella R KimmerlyGladstone Institutes, San Francisco, CA 94158.
Chia-Lin TsouGladstone Institutes, San Francisco, CA 94158.
Luis Martinez-SobridoTexas Biomedical Research Institute, San Antonio, TX, 78227, USA.
Nevan J KroganUniversity of California San Francisco, San Francisco, CA 94158.
Alan AshworthUniversity of California San Francisco, San Francisco, CA 94158.
James S FraserUniversity of California San Francisco, San Francisco, CA 94158.
Melanie OttGladstone Institutes, San Francisco, CA 94158.
Gladstone Institutes · USUniversity of California, San Francisco · USTexas Biomedical Research Institute · US

Funding

Targeting Viroporins and Coronavirus M ProteinU19AI171110 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI James Solomon Fraser · 2022 to 2026
$103.4M
User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI PAUL David ADAMS, Gregory L Hura · 2017 to 2026
$28.6M
The origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodiesR01AI161175 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KOBIE, JAMES J, MARTINEZ-SOBRIDO, LUIS · 2021 to 2024
$2.5M
Suppression of Host Antiviral Responses by a SARS-CoV-2 Histone MimeticF31AI164671 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHEN, IRENE PO-RU · 2021 to 2022
$82k
NIAID NIH HHS F31 AI164671NIAID NIH HHS R01 AI161175NIAID NIH HHS U19 AI171110NIGMS NIH HHS P30 GM124169
6 · The paper itself

Abstract

Despite unprecedented efforts, our therapeutic arsenal against SARS-CoV-2 remains limited. The conserved macrodomain 1 (Mac1) in NSP3 is an enzyme exhibiting ADP-ribosylhydrolase activity and a possible drug target. To determine the therapeutic potential of Mac1 inhibition, we generated recombinant viruses and replicons encoding a catalytically inactive NSP3 Mac1 domain by mutating a critical asparagine in the active site. While substitution to alanine (N40A) reduced catalytic activity by ~10-fold, mutations to aspartic acid (N40D) reduced activity by ~100-fold relative to wildtype. Importantly, the N40A mutation rendered Mac1 unstable

Identifiers

PMID37131711
PMCPMC10153184
OpenAlexW4366333935

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.